(Q36120804)

12 August 2017

1 reference

title

Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. (English)

1 reference

12 August 2017

1 reference

Steven-Huy B Han

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

14

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

511-519

1 reference

Natural history and prognostic factors for chronic hepatitis type B

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Asian-Pacific consensus statement on the management of chronic hepatitis B: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Antiviral L-nucleosides specific for hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.4.511

10.1517/13543784.14.4.511

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference